System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Published Erratum Epublish 1 citation

PubMed: 36376284 DOI: 10.1038/s41467-022-34580-3

Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer.

Nat Commun 13(1):6928

Authors: Marta Palafox, Laia Monserrat, Meritxell Bellet, Guillermo Villacampa, Abel Gonzalez-Perez, Mafalda Oliveira, Fara Brasó-Maristany, Nusaibah Ibrahimi, Srinivasaraghavan Kannan, Leonardo Mina, Maria Teresa Herrera-Abreu, Andreu Òdena, Mònica Sánchez-Guixé, Marta Capelán, Analía Azaro, Alejandra Bruna, Olga Rodríguez, Marta Guzmán, Judit Grueso, Cristina Viaplana, Javier Hernández, Faye Su, Kui Lin, Robert B Clarke, Carlos Caldas, Joaquín Arribas, Stefan Michiels, Alicia García-Sanz, Nicholas C Turner, Aleix Prat, Paolo Nuciforo, Rodrigo Dienstmann, Chandra S Verma, Nuria Lopez-Bigas, Maurizio Scaltriti, Monica Arnedos, Cristina Saura, Violeta Serra

Affiliations

  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Breast Cancer and Melanoma Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Department of Medical Oncology, Hospital Vall d'Hebron, Barcelona, Spain.
  • Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Institute for Research in Biomedicine (IRB Barcelona), Barcelona, Spain.
  • Research Program on Biomedical Informatics, Universitat Pompeu Fabra, Barcelona, Spain.
  • Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
  • Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
  • Oncostat U1018, Inserm, University Paris-Saclay, Villejuif, France.
  • Bioinformatics Institute (A*STAR), Singapore, Singapore.
  • Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.
  • The Breast Cancer Now Research Centre, London, UK.
  • Preclinical Modelling of Pediatric Cancer Evolution Group, The Institute of Cancer Research, London, UK.
  • Translational Molecular Pathology, Vall d'Hebron Institute of Research (VHIR), Barcelona, Spain.
  • Novartis Pharmaceuticals, East Hanover, NJ, USA.
  • Genentech, Inc. South San Francisco, California, USA.
  • Breast Biology Group, Manchester Breast Centre, Manchester, UK.
  • Cancer Research UK, Cambridge, UK.
  • CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Growth Factors Laboratory, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Department of Biochemistry and Molecular Biology, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
  • University of Barcelona, Barcelona, Spain.
  • Department of Medical Oncology, Hospital Clinic, Barcelona, Spain.
  • SOLTI Breast Cancer Research Group, Barcelona, Spain.
  • Department of Oncology, IOB Institute of Oncology, Barcelona, Spain.
  • Molecular Oncology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
  • Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
  • Departments of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, USA.
  • Department of Medical Oncology, Gustave Roussy, Villejuif, France.
  • Inserm Unit U981, Villejuif, France.
  • Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • CIBERONC, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

MeSH

Biological Science Disciplines, Biomarkers, Breast Neoplasms, Genes, P16